Welcome to our dedicated page for Skye Bioscience news (Ticker: SKYE), a resource for investors and traders seeking the latest updates and insights on Skye Bioscience stock.
Skye Bioscience (SKYE) is a clinical-stage biopharmaceutical innovator developing targeted therapies through cannabinoid receptor modulation. This page serves as the definitive source for verified company announcements, research milestones, and financial updates.
Investors and researchers will find timely updates on clinical trials, regulatory developments, and strategic partnerships. Our curated collection includes earnings reports, pipeline progress for nimacimab (peripheral CB1 inhibitor), and scientific presentations - all organized for efficient due diligence.
Key focus areas include metabolic disorder therapeutics, antibody-based drug development, and clinical safety data. Content is rigorously verified to ensure compliance with financial disclosure standards while maintaining accessibility for both specialist and general audiences.
Bookmark this page for structured access to SKYE's evolving position in biopharmaceutical innovation, with particular emphasis on obesity treatment research and peripheral endocannabinoid system modulation.
Skye Bioscience (OTCQB: SKYE) announced that Karam Takhar, VP of Corporate Development, will virtually present at the H.C. Wainwright Ophthalmology Conference on August 17 at 7:00 AM ET. The management team will also be available for one-on-one meetings during the event. Skye Bioscience develops cannabinoid-derived therapeutics aimed at addressing unmet medical needs, with its lead program targeting glaucoma, a major cause of blindness. Interested investors should contact their H.C. Wainwright representative for meeting arrangements.
Skye Bioscience has successfully completed genotoxicity studies of its proprietary synthetic cannabinoid THCVHS, a potential treatment for glaucoma. These studies, conducted under Good Laboratory Practices, indicated no chromosomal or gene mutations, a prerequisite for initiating Phase 1 clinical trials in Australia. CEO Punit Dhillon emphasized the significance of these findings for advancing to human trials and noted THCVHS's ability to lower intraocular pressure with minimal systemic exposure.
Skye Bioscience, Inc. (OTCQB: SKYE) has appointed Praveen Tyle, Ph.D., as an independent director to its board. Dr. Tyle brings over 35 years of pharmaceutical industry experience and leadership in various roles. CEO Punit Dhillon expressed confidence in Dr. Tyle's ability to contribute to advancing Skye’s lead clinical program and expanding its development portfolio. Dr. Tyle is currently President and CEO of Invectys and has held senior positions at major pharmaceutical companies. Skye focuses on developing cannabinoid-derived therapies for diseases with significant unmet needs, including glaucoma.
Skye Bioscience, Inc. (OTCQB: SKYE) announced the appointment of Dr. Miguel González-Andrades to its Clinical Advisory Board, a significant move as the company approaches its first-in-human study for THCVHS, targeting glaucoma treatment. CEO Punit Dhillon emphasized the value Dr. González-Andrades brings with his extensive ophthalmology experience. The Clinical Advisory Board also includes renowned experts like Jeffrey Goldberg and Robert Ritch, enhancing the company's capabilities to address unmet medical needs in ophthalmology.
Skye Bioscience (SKYE) announced promising results from a preclinical study of its THCVHS prodrug combined with netarsudil. The combination achieved a maximum intraocular pressure (IOP) reduction of 32.4%, with a sustained reduction of 26.5% at nine hours, outperforming standard therapies like latanoprost. THCVHS alone demonstrated a 27.5% reduction in IOP, maintaining a 21.1% reduction over nine hours. This study reinforces THCVHS's potential as a leading glaucoma treatment and sets the stage for upcoming human trials, anticipated to commence later this year.
Skye Bioscience (SKYE) has initiated key steps in advancing its glaucoma treatment, THCVHS, into human clinical trials. The company has completed its Chemical, Manufacture and Controls (CMC) procedures necessary for GLP toxicology studies, which are crucial for FDA approval. Preclinical studies show THCVHS effectively lowers intraocular pressure, surpassing existing glaucoma treatments. Upcoming studies will assess THCVHS's neuroprotective properties and its combination efficacy with leading drugs. The Phase 1 human trial is expected to start by year-end, as regulatory approvals progress.
Skye Bioscience, Inc. (OTCQB: SKYE) announced that CEO Punit Dhillon will present a corporate overview at the upcoming Sequire Cannabis Investor Conference on April 20, 2021, at 12:30 PM EST, and at the Planet Microcap Showcase on April 22, 2021, at 10:30 AM EST. The company is focused on developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other unmet medical needs. Their lead molecule shows potential for lowering intraocular pressure in glaucoma patients, outperforming current treatments. For more details, visit www.skyebioscience.com.
Skye Bioscience (OTCQB: SKYE) announces CEO Punit Dhillon's participation in the Benzinga Biotech Small Cap Conference on March 25, 2021. He will engage in a virtual panel titled 'The Natural Solutions: Cannabis & Cannabinoids' at 11:40 AM EST and present a corporate overview named 'Unlocking the Pharmaceutical Potential of Cannabinoids' at 12:10 PM EST. The Company focuses on developing cannabinoid-derived molecules aimed at treating glaucoma and other serious diseases. Their lead candidate shows promise in lowering intraocular pressure, surpassing current treatments.
Skye Bioscience (OTCQB: SKYE) announced positive preclinical results for its THC prodrug, THCVHS, which showed no eye irritation in the EpiOcular TM MTT ET-50 assay. This non-irritating profile is vital for future clinical testing. Skye aims to develop cannabinoid-derived medicines with rigorous standards and will advance THCVHS into a Phase 1 study for glaucoma treatment anticipated in early 2022. The study's findings underscore the formulation's safety and support Skye's commitment to innovative therapeutic solutions for unmet medical needs.
Skye Bioscience (OTCQB: SKYE) announced the appointment of cannabinoid experts Giovanni Appendino, PhD, and Eduardo Muñoz, MD, PhD, to its scientific advisory board. CEO Punit Dhillon emphasized the significance of their expertise in advancing cannabinoid-based medicines. Dr. Appendino brings over 40 years of research experience, while Dr. Muñoz has significant expertise in cannabinoid pharmacology and inflammation. Their contributions aim to enhance Skye's pipeline, particularly its lead molecule targeting glaucoma, which has shown promise in preclinical studies.
